Core Viewpoint - Nxera Pharma Co. Ltd will announce its earnings results and operational highlights for the year ended 31 December 2025 on 13 February 2026, with a live webinar presentation featuring key executives [1][2]. Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines to address unmet patient needs in Japan and globally [2]. - The company has established a new-generation commercial business in Japan, aiming to develop and commercialize innovative medicines for a large and growing market in the APAC region [2]. - Nxera Pharma utilizes its unique NxWave™ GPCR structure-based drug discovery platform to advance an extensive pipeline, both internally and in collaboration with leading pharmaceutical and biotech companies [2]. - The company operates in key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [2]. Webinar Details - The upcoming webinar is open to existing and potential investors, as well as sell-side and buy-side analysts, featuring a presentation followed by a Q&A session [2]. - Presentation slides will be available on the investor section of the company's homepage by 4:30 pm JST on 13 February 2026 [2].

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced a significant milestone in the development of its obesity drug VK2735. Viking Therapeutics, Inc. (VKTX) Targets $150B Obesity Drug Market amid VK2735 Topline Results Data published in the peer-reviewed journal Obesity show that the drug achieved a weight loss of 14.7% from baseline after 13 weeks of treatment, with no plateau observed. The clinical trial ...

Core Insights - HanchorBio and WuXi Biologics have signed a strategic collaboration agreement to develop and manufacture next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline [1][3][4] Company Overview - HanchorBio is a global clinical-stage biotechnology company focused on advancing immunotherapies for oncology and autoimmune diseases, utilizing its proprietary Fc-Based Designer Biologics (FBDB™) platform [1][8][9] - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics development and manufacturing [10][11] Collaboration Details - Under the agreement, WuXi Biologics will offer integrated services including cell line development, process and bioassay development, drug product formulation, and GMP manufacturing to support HanchorBio's innovative fusion protein portfolio [3][4] - The partnership aims to enhance clinical translation, improve CMC execution efficiency, and support scalable global development and manufacturing [3][4] Strategic Goals - HanchorBio's strategy focuses on advancing its multi-asset pipelines with speed, robustness, and capital efficiency from early clinical stages to commercialization [4][6] - The collaboration is expected to shorten development timelines and maintain flexibility across multiple clinical programs [4][6] Expertise and Capabilities - WuXi Biologics has extensive experience in complex modalities, supporting 945 projects as of 2025, with approximately 60% involving bi- and multi-specific antibodies, ADCs, and fusion proteins [5][11] - The company utilizes proprietary technology platforms to enhance speed, quality, and scalability in biologics development [5][11] Future Outlook - The partnership represents a significant step for HanchorBio in aligning discovery innovation with industrial-scale execution, advancing its oncology and autoimmune pipelines toward global clinical development [6][7]

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential violations of federal securities laws following disappointing clinical trial results that led to a significant drop in stock price [1][2]. Group 1: Company Performance - On December 29, 2025, Mereo BioPharma announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), reporting that neither study achieved its primary efficacy endpoint of reducing the annualized clinical fracture rate compared to placebo [2]. - Following the announcement, Mereo's stock price plummeted over 89%, opening at $0.25 per share [2]. Group 2: Legal Investigation - Levi & Korsinsky has commenced an investigation into Mereo BioPharma Group plc regarding potential violations of federal securities laws, inviting investors who suffered losses to explore recovery options [1][3].

Should the FDA approve the Leqembi Iqlik 500 mg subcutaneous (SC) dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly intravenous (IV) dosing. This would enable patients and care partners to choose SC administration at home for both treatment initiation and the currently approved maintenance therapy (360 mg), offering the option of SC or IV administration throughout the entire treatment journey. The inje ...

Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established a robust and diverse pipeline of RNAi molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases. Currently, Argo Biopharma has six RNAi candidates in clinical development. For more information, visit www.a ...

Company Overview - Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases, leveraging a diversified portfolio of approved products and a clinical pipeline targeting high-need indications [6] - The company generates revenue from commercialized rare disease therapies, including Chenodal, Cholbam, and Thiola/Thiola EC, and has additional pipeline assets such as Sparsentan and TVT-058 in clinical development [8] Financial Performance - As of January 16, 2026, Travere Therapeutics' stock price was $27.87, with a market capitalization of $2.46 billion [4] - The company reported a total revenue of $435.83 million for the trailing twelve months (TTM), with a net income of -$88.54 million [4] - In the third quarter, sales of the FILSPARI drug increased by 155% year over year to $90.9 million, contributing to total revenue of $164.9 million, up from $62.9 million the previous year [10] Investment Activity - Palisades Investment Partners, LLC initiated a new position in Travere Therapeutics, acquiring 137,768 shares valued at approximately $5.26 million [2] - This new position represents 1.99% of Palisades Investment Partners' $264.72 million in reportable U.S. equity assets as of December 31, 2025 [3] - The stock price of Travere Therapeutics increased by 50.89% over the past year, outperforming the S&P 500 by 34.01 percentage points [3] Market Position and Growth Potential - Travere Therapeutics is well-positioned to address unmet medical needs in the rare disease market, supported by strategic partnerships and clinical research initiatives [6] - The company's focus on rare metabolic and renal disorders, along with the potential expansion of FILSPARI's use pending FDA approval, suggests strong growth prospects [11]

Company Performance - Halozyme reported strong third-quarter results with record revenue of $354 million, a 22% increase year over year, and earnings per share (EPS) of $1.43, up 36% from the previous year [1] - The company reduced its net long-term debt from $1.5 billion to $800 million, indicating improved fiscal health [1] Revenue Sources - The increase in revenue includes $236 million from royalty revenue, which rose by 52% compared to the same period last year, partly due to the approval of Opdivo for subcutaneous use in Europe [1][2] - Halozyme's Enhanze drug-delivery platform is utilized in 10 drugs, including major cancer therapies like Herceptin and Darzalex Faspro [3] Market Position and Strategy - Halozyme operates as a "pick-and-shovel" stock, focusing on drug-delivery systems rather than therapies, which allows for lower costs compared to many biotech firms [4] - The company is in the process of acquiring Elektrofi, a competitor with a different drug-delivery system, which may enhance its market position [4] Future Outlook - Halozyme forecasts annual revenue between $1.3 billion and $1.375 billion, representing a growth of 28% to 35%, and expects EPS to rise to between $6.10 and $6.50, an increase of at least 44% [8] - The company is well-positioned for growth due to its low debt levels and strong revenue projections, which could provide significant returns for investors [14][15] Industry Context - The biotech sector has shown signs of recovery, with the SPDR S&P Biotech ETF rising 27% in 2025, indicating a positive trend for companies like Halozyme [6] - Both Halozyme and Catalyst Pharmaceuticals are noted for their profitability and relatively low valuations compared to the sector average, suggesting potential for investment [13][14]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Knature Biopharmaceutical Co., Ltd. 康 諾 生 物 製 藥 股 份 有 限 公 司 (the "Company") (A joint stock company incorporated in the People's Republic of China ...

Group 1: Institutional Investment Activity - Arkadios Wealth Advisors increased its position in AstraZeneca by 62.6% in Q3, owning 18,205 shares valued at $1,397,000 after purchasing an additional 7,010 shares [2] - Other institutional investors also adjusted their stakes, with Chapin Davis Inc. increasing holdings by 3.3% to 3,795 shares worth $291,000, CoreCap Advisors LLC raising its position by 30.6% to 534 shares valued at $41,000, and Highline Wealth Partners LLC lifting holdings by 32.0% to 532 shares also worth $41,000 [3] - Hedge funds and institutional investors collectively own 20.35% of AstraZeneca's stock [3] Group 2: Analyst Ratings and Forecasts - Wall Street analysts have mixed ratings for AstraZeneca, with nine analysts rating it as a "Buy" and one as a "Sell," resulting in an average rating of "Moderate Buy" and a consensus target price of $95.75 [4] - Jefferies Financial Group initiated coverage with a "buy" rating, while Barclays and TD Cowen reaffirmed their "overweight" and "buy" ratings respectively [4] Group 3: Financial Performance - AstraZeneca reported Q3 earnings of $1.19 per share, exceeding the consensus estimate of $1.14 by $0.05, with revenue of $15.19 billion, up 12.0% year-over-year [6] - The company had a return on equity of 32.89% and a net margin of 16.17% [6] Group 4: Company Overview - AstraZeneca is a global biopharmaceutical company based in Cambridge, England, formed through the merger of Astra AB and Zeneca Group in 1999 [7] - The company focuses on various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases [8]